Edgewise TherapeuticsEWTX
Market Cap: $2.65B
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Employees: 97
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
657% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $140K
97% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 30
50% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 22
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
10.01% more ownership
Funds ownership: 98.82% [Q1] → 108.83% (+10.01%) [Q2]
9% more capital invested
Capital invested by funds: $1.68B [Q1] → $1.83B (+$153M) [Q2]
9% more funds holding
Funds holding: 129 [Q1] → 140 (+11) [Q2]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
RBC Capital Leonid Timashev 44% 1-year accuracy 14 / 32 met price target | 49%upside $42 | Outperform Maintained | 20 Sept 2024 |
Truist Securities Srikripa Devarakonda 64% 1-year accuracy 14 / 22 met price target | 17%upside $33 | Buy Maintained | 19 Sept 2024 |
RBC Capital Leonid Timashev 44% 1-year accuracy 14 / 32 met price target | 13%upside $32 | Outperform Maintained | 17 Sept 2024 |
Wedbush Laura Chico 49% 1-year accuracy 36 / 74 met price target | 10%upside $31 | Outperform Reiterated | 16 Aug 2024 |
JP Morgan Tessa Romero 39% 1-year accuracy 7 / 18 met price target | 10%upside $31 | Overweight Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 7 articles about EWTX published over the past 30 days